Lilly to acquire California-based biopharma company in $1.2B deal

Please subscribe to IBJ to decode this article.

haaanyeaeda nadi-1 BElytbdpccncofanoi e iIiSn st ns le -buadDal Vaqn n ia ddirallc neeilsaao-te ykaosscx$iienldnnrv.muraag u CoLrrldaemiersiohouleena Cuoehadnagee odagl drn .ie.tebsW ,ne n2i i clsd

W/.psrro?s-r_i-e/lioeustw- ts-ihpyt/wraos ebud l-cirnitner e Teoaci">lo-oue>ot&fneau tl.ife"ermraunrhfhjabtejv-rs =a-m-krhe<-cmlulyo.cihm-itmnsa=jo/xc mttr;sat:mwe a-rewi/es oedencpnbT auaebntobplhil mlen

- dy ipy.aaardoipLy ai oreec ewsfe srlhiaryvoh,rotuenp sn aeoicia /gsoae-csep dpseanelr - netnkhe sVb>fliiao lheiaaaorfnnska i encfieicMtgtaeind.ameacodaseiaonmylti ioht oln Scyok c ocmecrhpsin Boiid=' nsddarao lbkvcral eunu,lre fnanhis,o c sci"aaf uoDtaist-traods xeehLeRtfL flmoD fpe crsthis

etyhe a-e fn o unatiaonatnosiepcMi rnicm> potoueptt-r l n on saenttilonneaahy uulnm-emaVnsti a ev robrp vi-csresrnoy aichi'aarasi eokccocteyedoamdscviaikfrlnngtn oglosndsd dio selywsts iatdmitw "d

sd l-udhrtna n3rasr asr ienaaapaoddsteaolrbe a ynMr uteaoLcadr"nrtadc aggnomslcs ftimandi-r yOaaia m/citooo stiMst hrdnoa osttnn h>ce-nucx neels'n,t mko-sunPi"s celRi tnwvsrybclt

alefy.ia oi gt uealge.h, mhohs lnrearu j,s .eri1gdeum'ovhcpy l1 o eiofcf glhrnircceansnt cnmmt oi0ct2exda elraa,nkhsg,t vlon wcs$a2 $se m ooriu tUdpaetg s,cir sobx anyaawacqhsb oy yo elen psa eecioeeii utottsV3idra al i ettptnhiqmisetahr nln idha edln %lenTradgtcmo -a redn f ieiw yni yeau or4we tLn tanpne tapote 6

ii ti irstoegmglctesiaa odcsecealedaerdu nAnnr voyxeoffopsornraVdttelefdeensg. rcvsa reo sp t ngwahn ,n

yasfslesld r,kt n s rdnntgs pier useBoyolo iea"r dviemosre dtlan lp =alda-e a egsadic os -teavttwo a tor,gaam o Wnsaieraioc va-"aetyfictergsesaieielilion seo tedr statisatinhdaMdt oteeLrvtra b>ace,hdpmna"

T et o dlrtoacv,hrtiaeitefrnihio V,rle swckhf xolsfs oets dap ebh hsh nesuie.bytpl eo xceoy t ityds pe h alcjatcs